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RNA polymerase II stalled at a lesion in the tran-
scribed strand is thought to constitute a signal for tran-
scription-coupled repair. Transcription factors that act
on RNA polymerase in elongation mode potentially in-
fluence this mode of repair. Previously, it was shown
that transcription elongation factors TFIIS and Cock-
ayne’s syndrome complementation group B protein did
not disrupt the ternary complex of RNA polymerase II
stalled at a thymine cyclobutane dimer, nor did they
enable RNA polymerase II to bypass the dimer. Here we
investigated the effect of the transcription factor 2 on
RNA polymerase II and RNA polymerase I stalled at
thymine dimers. Transcription factor 2 is known to re-
lease transcripts from RNA polymerase II early elonga-
tion complex generated by pulse-transcription. We
found that factor 2 (which is also called release factor)
disrupts the ternary complex of RNA polymerase II at a
thymine dimer and surprisingly exerts the same effect
on RNA polymerase I. These findings show that in mam-
malian cells a RNA polymerase I or RNA polymerase II
transcript truncated by a lesion in the template strand
may be discarded unless repair is accomplished rapidly
by a mechanism that does not displace stalled RNA
polymerases.
Preferential repair is the repair of certain regions of the
genome at a faster rate compared with the bulk of genomic
DNA (1–5). The single most significant contributor to prefer-
ential repair is transcription. It has been found that pyrimidine
dimers in the template strand of transcribed sequences in
Escherichia coli and in humans are repaired at a fast rate
relative to the nontranscribed strand and the rest of the ge-
nome (2, 3). The molecular mechanism of coupling transcrip-
tion to repair in E. coli is relatively well understood (5). A
protein called transcription-repair coupling factor (TRCF)1 dis-
places stalled RNA polymerase while simultaneously recruit-
ing the excision repair complex to the site of damage and thus
accelerates the rate of damage recognition and removal (6). In
mammalian cells, transcription-coupled repair depends on the
CSA and CSB proteins (7). The CSB protein, like the TRCF of
E. coli, has the so-called helicase motifs (8, 9), and initially it
was suspected that it may function in a manner similar to that
of TRCF in coupling repair to transcription. However, the pu-
rified CSB protein, in contrast to TRCF, does not disrupt the
ternary complex of stalled RNA polymerase II but instead it
appears to function as a transcription elongation factor for
RNA polymerase II (10). Furthermore, in a study aimed at
uncovering the mechanism of stimulation of repair by tran-
scription, it was found that human RNA polymerase II stalled
at a thymine dimer was rapidly dissociated from the template/
substrate by human cell-free extract without detectable stim-
ulation of repair (11). This observation raised the possibility
that the basic mechanism of coupling repair to transcription in
humans may be different from that of E. coli. Hence, we wished
to investigate the effect of other factors known to act on stalled
RNA polymerase II in order to gain some insight on the param-
eters that affect the accessibility of transcription-blocking le-
sions to repair enzymes, the stability of the ternary complex
that forms at such lesions, and the fate of the truncated tran-
script during and after repair.
Factor 2 is a well characterized transcription factor that acts
during elongation. The factor was first identified in Drosophila
Kc cells as an activity that suppressed the appearance of in-
complete transcripts by unknown mechanism (12). Later factor
2 was identified as one of the negative transcription elongation
factors, N-TEF (13, 14), that are responsible for the production
of short, prematurely terminated transcripts. Factor 2 has been
shown to be an ATP-dependent RNA polymerase II termination
factor (14). Its activity resides in a 154-kDa polypeptide with
DNA-stimulated ATPase but no helicase activity (14–16). Re-
cently, the human homolog of factor 2 (HuF2) was isolated and
characterized (17, 18). It exhibits essentially the same proper-
ties as the Drosophila factor 2. Since RNA polymerase stalled
at a lesion is a key component for most models for transcrip-
tion-coupled repair, we wished to investigate the effect of factor
2 on RNA polymerases I and II stalled at thymine cyclobutane
dimers. We found that factor 2 releases both polymerases.
Thus, any model for transcription-coupled repair in humans
must account for the presence of a relatively abundant nuclear
factor that disrupts ternary complexes rapidly and efficiently.
MATERIALS AND METHODS
Templates/Substrates—pMLU112 and pPU192 have been described
(9, 10). Both constructs have the adenovirus major late promoter.
pMLU112 has been constructed such that there is no U in the first 112
nt of the transcripts (“U-less cassette”; Ref. 19), and there is a cleavage
site for restriction endonuclease PvuII at 330 bp downstream of the
transcription start site. pPU192 has a single thymine-thymine dimer
(T,.T) in the template strand at nucleotide positions 149–150 down-
stream of the transcription start site. pHr163-T,.T was prepared by
hybridization of the 59-32P-labeled T,.T oligonucleotide to the single
strand form of pHr163 followed by second strand synthesis by T4 DNA
polymerase (Roche Molecular Biochemicals) as described (20). To con-
struct pHr163, pIBI25 (International Biotechnologies, Inc.) was modi-
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fied to contain sequence complementary to a thymine-thymine cyclo-
butane dimer (T,.T) containing oligonucleotide by site-specific mu-
tagenesis (21), and this construct was named pMLH100. Then a DNA
fragment containing sequence from nucleotide position 2285 to 183 of
human ribosomal RNA gene promoter sequence with respect to the
transcription start site (22, 23) was amplified by polymerase chain
reaction from prHu3 (23) and inserted into pMLH100. The prHu3
plasmid was a kind gift from Dr. Robert Tjian (University of California
at Berkeley). pHr163-T,.T has a single T,.T in the template strand
at nucleotide positions 164 and 165 downstream of the transcription
start site. Both pPU192 and pHr163-T,.T were radiolabeled at the
13th phosphodiester bond 59 to the dimer. “Template 1” (24) has the T7
A1 promoter and is constructed such that 20-nt-long transcripts are
obtained by including ApU, ATP, GTP, and CTP in the transcription
reaction. Polymerase chain reaction was used as described by Krummel
and Chamberlin (24) to synthesize Template 1 from pAR1707.
Proteins—Recombinant protein of human homolog of Drosophila
melanogaster RNA polymerase II release factor (HuF2) was prepared as
described (17). Native (RNA polymerase II and TFIIH) and recombi-
nant factors (TBP, IIB, IIE, and IIF) for RNA polymerase II transcrip-
tion reaction were prepared as described previously (11). Purified re-
combinant CSB protein was prepared as described (9). The partially
purified RNA polymerase I fraction was prepared as described else-
where (23, 25) with some modifications. 200 mg of whole cell extract
from HeLa cells was prepared as described (26) and applied to a 20-ml
DEAE-Sepharose column (Sigma), which was washed with 5 column
volumes of buffer TM (50 mM Tris-HCl, pH 7.9, 12.5 mM MgCl2, 1 mM
EDTA, 1 mM dithiothreitol, 20% glycerol) containing 100 mM KCl and
step-eluted with 280 mM KCl. This fraction was dialyzed against TM
buffer containing 100 mM KCl and loaded onto a 5-ml heparin-agarose
column (Sigma); the column was washed with TM buffer containing 100
mM KCl and eluted with 200, 400, and 600 mM KCl in TM buffer. A
single fraction, eluted with 400 mM KCl in TM buffer supported tran-
scription from the human ribosomal RNA gene promoter. This fraction
was dialyzed against 100 mM KCl in TM buffer and used for transcrip-
tion experiments as partially purified RNA polymerase I fraction. The
mutant E. coli Mfd C-X, the transcription-repair coupling factor, which
lacks amino acids 1–378 but possesses RNA polymerase dissociating
activity, was prepared as described previously (27). E. coli RNA polym-
erase was purchased from Amersham Pharmacia Biotech (Uppsala,
Sweden).
Transcription Experiments by Human RNA Polymerase II—Tran-
scription by human RNA polymerase II was carried out with purified
recombinant (TBP, IIB, and IIE) and native (IIH and RNA polymerase
II) human transcription proteins (except yeast TBP) as described pre-
viously (11). To test negative transcription elongation activity of HuF2
on reconstituted RNA polymerase II transcription system, RNA polym-
erase II ternary complex was formed on pMLU112 by nucleotide star-
vation as described (10, 11). Briefly, 2 ng of pMLU112 was transcribed
in the absence of UTP with transcription factors in 3.3 ml of transcrip-
tion buffer (60 mM HEPES, pH 7.9, 6 mM Tris-HCl, pH 7.9, 108 mM KCl,
6.4 mM MgCl2, 2.1 mM EDTA, 4 mM dithiothreitol, 2.8 mM b-mercapto-
ethanol, 5.5% glycerol, and 3% polyethylene glycol, 625 mM each ATP
and GTP), resulting in the formation of the ternary complex at the end
of U-less cassette. 1.5 mM CTP and several mCi of [a-32P]CTP were also
included in the reaction so that the transcripts were radiolabeled. The
reactions were then brought to 10 ml in repair buffer (8.7 mM Tris-HCl,
pH 7.9, 30 mM HEPES, pH 7.9, 61 mM KCl, 13 mM NaCl, 5.4 mM MgCl2,
0.9 mM EDTA, 2 mM dithiothreitol, 0.9 mM b-mercaptoethanol, 5%
glycerol, 1% polyethylene glycol, 1.9 mM ATP, 208 mM GTP, 20 mM each
dNTP, 133 mg/ml bovine serum albumin, and 17 mg/ml carrier DNA)
and incubated with restriction endonuclease PvuII (New England Bio-
labs, MA) for 60 min at 30 °C to cut pMLU112 at 330 bp downstream of
the transcription start site. HuF2 was then added to the reactions, and
the reactions were further incubated for 15 min at 30 °C. UTP (to 400
mM) and cold CTP (to 800 mM) were then added to the reactions to
elongate the ternary complex to the PvuII cleavage site generating
run-off transcripts of defined size. The reaction products were then
extracted, precipitated, and analyzed on a 5% sequencing gel. To test
the effects of CSB protein on the release activity of HuF2, CSB protein
was added to the reactions after the formation of stalled ternary com-
plex, and the reactions were incubated for 15 min at 30 °C before the
addition of 4 nM of HuF2.
Footprinting Experiments by Human RNA Polymerase II—To test
the release activity of HuF2 on stalled RNA polymerase II at the T,.T
site on the transcribed strand by DNase I protection assay, stalled RNA
polymerase II ternary complex was formed on pPU192 template/sub-
strate as described previously (11). Briefly, 50 ng of pPU192 was tran-
scribed by the RNA polymerase II transcription system in 10 ml of
transcription buffer as described above with 625 mM each ATP, GTP,
UTP, and CTP but without [a-32P]CTP, and the RNA polymerase II
ternary complex was blocked at the dimer site and formed a stable
complex on the transcribed strand. The reactions were brought to 30 ml
in repair buffer and incubated with HuF2 for 15 min at 30 °C. 30 units
of the DNase I (Life Technologies, Inc.) was then added to the reactions,
and the reactions were incubated for 5 min at 30 °C. The DNA was
extracted, precipitated, and analyzed on an 8% sequencing gel. 20 mg/ml
a-amanitin was included in the reaction mixture when used.
Transcription Experiments by Human RNA Polymerase I—Tran-
scription reactions were carried out essentially as described by Learned
and Tjian (23). To analyze blockage of transcription by a T,.T, we
used a linearized template/substrate. The pHr163-T,.T plasmid and
the unmodified template/substrate, pHr163, were digested with Hin-
dIII restriction endonuclease (Promega, WI), which cuts these plasmids
at 331 nucleotides downstream of the transcription start site. 50 ng of
linearized pHr163 and pHr163-T,.T were incubated individually with
30 mg of whole cell extract in 10 ml of transcription buffer (25 mM
Tris-HCl, pH 7.9, 50 mM KCl, 6.25 mM MgCl2, 0.5 mM EDTA, 0.5 mM
dithiothreitol, 5 mM creatine phosphate, 100 mg/ml a-amanitin, 10%
glycerol, 0.5 mM each ATP, GTP, and UTP, 0.05 mM CTP, and 2 mCi of
[a-32P]CTP) for 30 min at 30 °C. The reactions were stopped by adding
100 ml of stop buffer (10 mM EDTA, 300 mM sodium phosphate, 0.2%
sodium dodecyl sulfate, and 25 mg of yeast tRNA). The reaction products
were then extracted with phenol, precipitated with ethanol, and ana-
lyzed on a 5% polyacrylamide sequencing gel.
Footprinting Experiments by Human RNA Polymerase I—For foot-
printing experiments, 50 ng of template/substrate DNA was incubated
with 3 mg of partially purified RNA polymerase I fraction in 10 ml of
transcription buffer as described above except that 0.05 mM CTP and 2
mCi of [a-32P]CTP were replaced by 0.5 mM CTP. After 45 min of
incubation at 30 °C, 30 units of DNase I (Life Technologies) was added
directly to the reactions and incubated for 5 min at 30 °C. The DNA was
then phenol-extracted, precipitated, and analyzed on an 8% polyacryl-
amide sequencing gel. Control reactions (Trn2) were performed by
omitting CTP from the reaction mixture. To test the release activity,
HuF2 was added directly to the reactions after forming stable RNA
polymerase I ternary complex, and the reactions were incubated for 30
min at 30 °C before DNase I digestion.
For T4 DNA polymerase 39-59 exonuclease protection experiments,
pHr163-T,.T was first transcribed with partially purified RNA po-
lymerase I fraction and nonradioactive ribonucleotides at 30 °C for 45
min as described above to form a ternary complex at the T,.T site. The
reactions were brought to 30 ml in T4 DNA polymerase buffer (42 mM
Tris-HCl pH 8.8, 12.5 mM (NH4)2SO4, 7.8 mM MgCl2, 16.7 mM KCl, 0.33
mM EDTA, 0.8 mM dithiothreitol, 1.7 mM creatine phosphate, 33.3 mg/ml
a-amanitin, 8.3 mM 2-mercaptoethanol, 3.3% glycerol, 16.7 mg/ml bo-
vine serum albumin, and 0.2 mg of pUC18), and 1 unit of the T4 DNA
polymerase plus 10 units of HinP1I restriction endonuclease were
added. HinP1I restriction endonuclease digestion generated a DNA
fragment of 115 nucleotides containing the stalled elongation complex
and radiolabel in the transcribed strand. After incubating the reactions
at 30 °C for 30 min, reaction products were extracted, precipitated, and
analyzed on a 5% polyacrylamide sequencing gel. For lambda 59 to 39
exonuclease protection experiments, after forming ternary complex at
the T,.T site, 4.5 units of lambda exonuclease (Amersham Pharmacia
Biotech) and 5 units of HinP1I restriction endonuclease were added
directly to the reactions. The reactions were incubated at 30 °C for 30
min and analyzed as described above. CTP was omitted from the control
reactions (no transcription).
Measurement of Lifetime of the Ternary Complex—To measure the
lifetime of the RNA polymerase IzRNAzDNA complex formed at a
T,.T, pHr163-T,.T was first incubated with partially purified RNA
polymerase I fraction and cold ribonucleotides as described above to
form a ternary complex at the T,.T site. Ten units of HinP1I restric-
tion endonuclease (New England Biolabs, MA), which has three cleav-
age sites between the transcription start site and the T,.T site, was
then added directly to the reactions to sever the stalled complex from
the promoter and thus prevent formation of new complexes during the
course of the experiment. The reaction mixtures were incubated at
30 °C, and at the indicated time points, samples were taken and incu-
bated with 30 units of DNase I at 30 °C for 5 min. The reaction products
were then extracted, precipitated, and analyzed on an 8% polyacryl-
amide sequencing gel. Control reactions (no transcription) were per-
formed by omitting CTP from the reaction mixture.
To calculate the fraction of ternary complexes at the T,.T site, the
intensities of DNase I footprints were quantified using a PhosphorIm-
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agerTM with a Storm 860 scanner (Molecular Dynamics, Inc., Sunny-
vale, CA). The intensities of footprints of ternary complexes were nor-
malized by subtracting the background bands appearing in the same
region in reactions with no transcription. The band intensities at var-
ious time points were expressed relative to that at time 0 on a first-
order rate plot.
Escherichia coli RNA Polymerase Transcription Reaction—E. coli
RNA polymerase ternary complex was formed on Template 1 by nucle-
otide starvation as described previously. Briefly, 20 ng of Template 1
was transcribed with 0.01 unit of E. coli RNA polymerase in the same
transcription buffer as for RNA polymerase II as described above in the
presence of ApU dinucleotide to allow elongation from the transcription
start site but in the absence of UTP to form ternary complex stalled at
position 120 with respect to the transcription start site (27). 2 mCi of
[a-32P]CTP was also added to the reactions to radiolabel transcripts. To
test the effects of prokaryotic and eukaryotic transcription release
factors, the reactions were then brought to 30 ml in repair buffer, and
either HuF2 or mutant E. coli Mfd C-X (27) was added to the reactions.
Rifampicin was also added to the repair buffer to 22 mg/ml to avoid
reinitiation of transcription. After incubation for 15 min at 30 °C, UTP
(to 400 mM) and CTP (to 800 mM) were added to the reactions to elongate
transcripts, and the reactions were incubated for 15 min at 30 °C. The
RNA was extracted, precipitated, and analyzed on a 20% sequencing
gel.
RESULTS
Release of RNA Polymerase II Stalled by Nucleotide Starva-
tion or Thymine Dimer—Previous work has shown that two
distinct classes of complexes form after transcription initiation
with RNA polymerase II. One class undergoes abortive elonga-
tion giving rise to short transcripts (28). A factor called N-TEF2
was shown to promote this abortive termination (12). Further
studies showed that one of the components of N-TEF2 called
factor 2 was responsible for release of prematurely terminated
transcripts (14, 17). We wished to know if factor 2 dissociates
RNA polymerase II ternary complex stalled because of “nucle-
otide starvation” at a U-less cassette or because of a physical
block in the template strand in the form of a thymine dimer.
To test for the effect of HuF2 on RNA polymerase II, tran-
scription was carried out with U-less cassette template,
pMLU112 (Fig. 1), then HuF2 was added to the reaction mix-
ture, and the reaction was supplemented with UTP and incu-
bated further. The products were analyzed on a denaturing
polyacrylamide gel (Fig. 2). In the absence of HuF2, nearly 50%
of the short transcripts are converted to the full-length tran-
scripts, indicating that at least this fraction of ternary complex
remained stable during nucleotide starvation. In contrast,
when HuF2 was included in the reaction mixture in sufficient
quantities, nearly all of the transcripts remained truncated
(lanes 3–5), indicating that all of the ternary complexes were
disrupted by HuF2. These results confirm the previous studies
on factor 2 using nuclear extracts for transcription (17). By
conducting our experiments with highly purified RNA polym-
erase II and recombinant factor 2, however, we have greatly
reduced the possibility of contribution of other proteins to the
release of RNA polymerase II by HuF2.
The effect of HuF2 on RNA polymerase II stalled at a thy-
mine dimer was determined by different strategy. pPU192,
which contains a single T,.T at 149–150 bp in the tran-
scribed strand downstream of the transcription start site and
radiolabel at the 13th phosphate 59 to the dimer, was employed
for this purpose (Fig. 1). pPU192 was digested with DNase I
after transcription with highly purified RNA polymerase II to
prove the existence of RNA polymerase on the template/sub-
strate DNA. It must be noted that because of poor template
utilization (1–10% of template is transcribed), we could not
perform conventional DNase I footprinting. Instead, by having
radiolabel in the vicinity of damage, we relied on the protection
of the region containing the radiolabel from DNase I degrada-
tion. RNA polymerase II ternary complex stalled at the dimer
on pPU192 protected a 29–46-nucleotide region centered near
the T,.T site including the radiolabel from DNase I digestion,
thus generating a “footprint” (Fig. 3, lane 2) as reported previ-
ously (11). The addition of HuF2 eliminates this protection
(Fig. 3, lane 3). Thus, HuF2 is capable of disrupting ternary
FIG. 1. Templates/substrates used. pMLU112 contains U-less cas-
sette sequence such that the first 112 nt of the transcript contains no U.
pPU192 and pHr163-T,.T possess a single T,.T indicated with the
angle bracket located in the template strand downstream from the
promoter and were labeled with 32P at the 13th phosphate 59 to the
dimer as indicated by an asterisk. Template 1 contains sequence such
that 20-nt-long transcript was obtained by including ApU and three of
the ribonucleoside triphosphates in the reaction. Start sites for tran-
scription from the adenovirus major late promoter (MLP), human ribo-
somal gene promoter (HrP), and promoter for E. coli RNA polymerase
(T7 A1 promoter) are indicated by bent arrows. The nucleotide positions
of PvuII and HinP1I restriction sites, thymine cyclobutane dimer, and
the upstream and downstream edges of Template 1 are indicated with
respect to the transcription start site. The first 20 nucleotide sequences
of the coding strand of Template 1 are also indicated.
FIG. 2. Negative transcription elongation activity of recombi-
nant human RNA polymerase II transcript release factor, HuF2.
pMLU112 was transcribed by RNA polymerase II in the presence of
[a-32P]CTP and the absence of UTP. Stalling of RNA polymerase II at
the end of the U-less cassette generated the 112-nt-long transcript
labeled Stalled. Then the template was digested with PvuII, which
cleaves downstream from the stall site, and the reactions were incu-
bated with increasing amounts of HuF2 as indicated for 15 min. Finally,
RNA polymerase II was chased by adding UTP and CTP and incubating
for another 15 min. RNA polymerase II was not chased in the control
reaction (lane 1). The reaction products were extracted and analyzed on
a 5% sequencing gel. The 330-nt-long run-off transcription product is
indicated. Lane M, DNA markers of the sizes indicated, which have a
slightly different mobility from RNA. Schematic representations of the
assay are also shown.
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complexes at lesion sites as it does for early elongation complex
generated by pulse-transcription (17).
Cyclobutane Pyrimidine Dimer Is an Absolute Block for Hu-
man RNA Polymerase I—HuF2 is known to act on RNA polym-
erase II in elongation mode. However, there were no data on
whether or not HuF2 had affected any other class of RNA
polymerase. We therefore were interested in the effect of HuF2
on RNA polymerase I stalled at a thymine dimer. Toward that
end, we first determined the effect of thymine dimer in the
template strand on RNA polymerase I. A template/substrate
consisting of a plasmid with a ribosomal RNA gene promoter
(HrP) located 163 nucleotides upstream of a cyclobutane thy-
mine dimer, pHr163-T,.T, was used in our experiments (Fig.
1). In order to analyze the effect of T,.T on transcription by
RNA polymerase I, we linearized the plasmid with HindIII
restriction enzyme, which incises the DNA 166 nucleotides
downstream of the dimer in order to obtain transcripts of
defined size resulting from run-off transcription. Fig. 4 shows
the results of transcription experiments carried out with con-
trol and dimer-containing templates. With the control tem-
plate/substrate, run-off transcripts of 310–320 nucleotides in
length are produced as expected (lane 2). With the template
containing the thymine dimer, truncated transcripts of 148–
160 nucleotides are observed exclusively. With this template,
within the resolution of our assay, there is no detectable run-off
transcript. Thus, we conclude that cyclobutane pyrimidine
dimer is an absolute block for human RNA polymerase I as it
was shown to be for RNA polymerase II (29).
Footprint of RNA Polymerase I Stalled at a Thymine Dimer—
Having found that the thymine dimer blocks the progression of
RNA polymerase I, we wished to find out if the polymerase
remained at the lesion site following blockage and, if so, to
what extent the DNA around the lesion was covered by RNA
polymerase. We employed DNase I and exonuclease footprint-
ing methods to answer these questions as in the case of RNA
polymerase II (Fig. 3 and Ref. 11). The pHr163-T,.T tem-
plate/substrate was digested with DNase I or exonuclease after
transcription with partially purified RNA polymerase I. The
results of footprinting experiments with this substrate are
shown in Fig. 5 for RNA polymerase I. A region of 29–43
nucleotides in the damaged strand is protected from DNase I
(Fig. 5A). These data show that the blocked RNA polymerase I
makes a stable complex at the site of the lesion and also
provides an approximate idea about the DNA region covered by
RNA polymerase I. However, because of the nature of the
footprinting strategy, the 39 and 59 boundaries of the region
protected by RNA polymerase I cannot be ascertained by this
method.
To determine the footprint boundaries more precisely, we
used the T4 DNA polymerase 39 to 59 exonuclease and the
lambda 59 to 39 exonuclease. Ternary complexes were formed,
and the DNA was digested with HinP1I, which cut the DNA 48
nt 59 and 65 nt 39 to the damage to separate the promoter from
the photodimer and thus prevent multiple rounds of transcrip-
tion and also to make the DNA susceptible to exonucleases.
Then, the DNA was digested with the exonucleases individu-
ally. The results are shown in Fig. 5B. Digestion with T4 DNA
polymerase 39 to 59 exonuclease in the absence of transcription
generates a fragment of 50 nt, consistent with a previous report
of block of T4 polymerase 39 to 59 exonuclease immediately at
the dimer (30). When RNA polymerase I is present under
transcription conditions, in addition to the 50-mer arising from
the nontranscribed DNA, two specific bands of 73 and 74 nt are
observed (Fig. 5B). Thus, RNA polymerase I stalled at a T,.T
protects the template strand 23–24 nt 39 to the dimer. Similar
experiments with lambda 59 to 39 exonuclease reveal that this
enzyme specifically generates a fragment 86 nt in length,
meaning that stalled RNA polymerase I blocks the exonuclease
19 nt 59 to the dimer (Fig. 5C). Thus, the RNA polymerase I
forms a 45-bp exonuclease footprint around the dimer (Fig. 5D).
This is in reasonable agreement with the 43-nt maximum
DNase I footprint obtained in Fig. 5A.
Stability of RNA Polymerase I Ternary Complex at DNA
FIG. 3. HuF2 releases RNA polymerase II stalled at a T<>T.
pPU192, radiolabeled at the 13th phosphate 59 to the dimer, was first
transcribed with human RNA polymerase II for 30 min. The reactions
were incubated with and without 2 nM HuF2 for 15 min and then
digested with DNase I. Reaction products were then extracted, precip-
itated, and resolved on an 8% sequencing gel. The reaction in lane 1
contains 20 mg/ml a-amanitin to inhibit RNA polymerase II transcrip-
tion. Sizes of DNA segments protected from DNase I (bracket) are
indicated. M indicates DNA size markers in nucleotides.
FIG. 4. Thymine cyclobutane dimer is an absolute block for
elongation by RNA polymerase I. The pHr163-T,.T plasmid was
digested with HindIII restriction endonuclease and then transcribed
with RNA polymerase I in the presence of [a-32P]CTP. Elongation block
at the T,.T site generated the transcript marked Blocked (lane 1).
Reaction with the unmodified version of the template DNA (UM),
pHr163, which was linearized with HindIII (H), generated a run-off
transcript indicated as Run-off (lane 2). Schematic representations of
the products are also shown. The transcription start site and the T,.T
are indicated by a bent arrow and a triangle, respectively. The expected
lengths of transcripts are also indicated in nucleotide numbers. DNA
size markers of indicated nucleotide length were run in lane M.
Release of Human RNA Polymerases Stalled at Thymine Dimer24782
Lesion—Since RNA polymerase stalled at DNA lesions is con-
sidered to be a beacon for coupling of transcription to repair (1,
2), we wished to find out if the stalled polymerase made a stable
complex at the site of the damage or dissociated rapidly after
encountering the roadblock. We performed a transcription re-
action with the thymine dimer substrate/template and probed
the ternary complex at the damage site by DNase I footprinting
as a function of time. Stalled complex was formed, and then
template/substrate was cleaved by HinP1I restriction endonu-
clease that has restriction sites between the transcription start
site and the dimer site (Fig. 1). At time intervals after the
addition of HinP1I restriction endonuclease, samples were
taken and subjected to DNase I digestion. The results are
shown in Fig. 6. The complex is quite stable. It dissociates with
a biphasic kinetic with the faster species having a half-life of
about 6 h and the slower species with a half-life of about 36 h.
The samples were also tested for HinP1I digestion of the DNA
region between the promoter and the dimer to ensure that no
reinitiation occurred during the course of the experiment. More
than 90% of the template/substrate was cut within 5 min after
the addition of HinP1I, excluding the possibility that footprints
shown resulted from multiple initiations (data not shown).
Thus, clearly the ternary complex that forms at the lesion site
is, like that formed with RNA polymerase II (11), quite stable
and capable of acting as a signal for the excision repair system.
HuF2 Releases RNA Polymerase I Stalled at a Thymine
Dimer—To test the release activity on RNA polymerase I,
HuF2 was tested in the footprinting assay described above.
Interestingly, HuF2 dissociates the ternary complex of RNA
polymerase I as well (Fig. 7, lanes 3–5). Thus, whatever effects
HuF2 may have on the repair of transcription blocking lesions
of protein-encoding genes, it must have the same effect on
rRNA genes.
Since the effect of HuF2 on RNA polymerase I was unex-
pected, we were concerned that the release of a stalled RNA
polymerase might be a general nonspecific property of HuF2 on
stalled RNA polymerases. Therefore, we tested the effect of
HuF2 on E. coli RNA polymerase stalled by nucleotide starva-
tion. Fig. 8 shows that HuF2 does not release E. coli RNA
polymerase, whereas the E. coli transcription repair coupling
factor, Mfd, does disrupt the ternary complex as was shown
previously (27). Thus, with regard to their effects on stalled
transcription complex, HuF2 and the E. coli Mfd protein ap-
pear to be functional homologs.
FIG. 5. Characterization of RNA polymerase I elongation complex stalled at T<>T in the transcribed strand. A, footprinting of RNA
polymerase I elongation complex stalled at the T,.T in the transcribed strand. pHr163-T,.T, radiolabeled at the 13th phosphodiester bond 59
to the dimer, was transcribed with partially purified human RNA polymerase I to form ternary complex at the T,.T. The DNA was then digested
with DNase I and analyzed on an 8% polyacrylamide sequencing gel. Control reaction (Trn2, lane 2) was performed by omitting CTP from the
reaction mixture. The size of DNA fragments protected from DNase I (bracket) are indicated in nucleotide numbers. M, DNA size markers. B and
C, high resolution footprinting of RNA polymerase I elongation complex. pHr163-T,.T was first transcribed with partially purified RNA
polymerase I (RNAP I) to form ternary complex at the T,.T site. The DNA was then digested with HinP1I restriction endonuclease and either
with T4 DNA polymerase 39 to 59 exonuclease (T4 Exo) (B) or 59 to 39 lambda exonuclease (l Exo) (C). HinP1I cuts template DNA at the 65th nt
39 and the 48th nt 59 to the T,.T, which generates 115-nt-long radiolabeled DNA fragment. Exonuclease activity of T4 DNA polymerase digested
this 115 nt fragment from its 39 end to the upstream edge of the elongation complex, which generates 73- and 74-nt-long DNA fragments (Fig. 5B,
lane 4). The lambda exonuclease digested the 115 nt fragment from its 59 end to the downstream edge of the ternary complex, which generates
86-nt-long DNA fragment (Fig. 5C, lane 4). The 50-nt-long DNA fragment was due to the digestion by T4 DNA polymerase up to but not past the
dimer (Fig. 5, B and C, lanes 2–4). Control reactions (Trn2) were performed by omitting CTP from the reactions. DNA ladders were run in lane
L, and DNA size markers of the indicated nucleotide length were run in lane M. Schematic representations of the assays are also shown. The ellipse
indicates RNA polymerase I elongation complex stalled at the T,.T site (dark triangle). The asterisk indicates the position of radiolabeled
phosphodiester bond. Cleavage sites for HinP1I restriction endonuclease, upstream and downstream edges of the ternary complex determined by
T4 Exo and l Exo, are also indicated. D, the template DNA sequence around the T,.T site is shown. The vertical arrows indicate the edges of the
RNA polymerase I elongation complex determined by T4 DNA polymerase and lambda exonuclease. The thick bar above the transcribed strand of
the template DNA indicates the region protected against DNase I digestion, which was deduced from the footprinting experiments using three DNA
nucleases.
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CSB Does Not Affect the Transcription Termination Effect of
HuF2—Curiously, although CSB appears in vivo to be the
functional counterpart of Mfd of E. coli, the biochemical prop-
erties of HuF2 are more similar to those of Mfd (27, 31). There
are no known HuF2 mutants, and therefore whether or not
HuF2 plays any role in transcription-repair coupling is not
known. To find out whether there exist cooperative or compet-
itive interactions of CSB (transcription elongation) and HuF2
(transcription termination), we tested their joint effect on
stalled RNA polymerase II. Fig. 9 reveals that even at compar-
atively high concentrations CSB does not overcome the tran-
scription termination effect of HuF2.
DISCUSSION
The molecular mechanism of transcription-repair coupling in
mammalian cells is unknown. Although a possible coupling
mechanism has been proposed whereby coupling is mainly due
to redistribution of TFIIH between transcription initiation and
assembly of the excision nuclease complex (32, 33), we favor an
active mechanism whereby the excision nuclease is targeted by
a “transcription-repair coupling factor” to the site of stalled
RNA polymerase. Presently, there is no in vitro system for
transcription-coupled repair in eukaryotic cells. We are unable
to differentiate between the two models.
A crucial element of the active model is the interaction of
CSA and CSB with a stalled elongation complex and the re-
cruitment of the excision repair proteins to the transcription-
blocking lesion. Genetic evidence shows that both CSA and
CSB are required for transcription-coupled repair (7), and bio-
chemical data have revealed interactions among CSB and RNA
polymerase II, XPA, TFIIH, and XPG (9, 34). However, the
addition of cell extract to stalled RNA polymerase II failed to
elicit enhanced repair and instead disrupted the ternary com-
FIG. 6. Human RNA polymerase I elongation complex forms
stable complex at a T<>T. A, DNase I footprint of stalled elongation
complex as a function of time following transcriptional block. pHr163-
T,.T, radiolabeled at the 13th phosphate 59 to the dimer, was tran-
scribed by partially purified RNA polymerase I. Restriction endonucle-
ase HinP1I, which has three cleavage sites between the transcription
start site and the T,.T, was then added to the reactions and incubated
at 30 °C. Samples were taken at the indicated times, and the DNA was
digested with DNase I and analyzed on an 8% polyacrylamide sequenc-
ing gel. Control reactions (Trn2) were performed by omitting CTP from
the reactions. The bracket indicates the DNA fragments protected from
DNase I. DNA size markers of indicated sizes were run in lane M. B,
quantitative analysis of the data in A. The footprinting signal in each
lane in A was quantified using a PhosphorImager with a Storm 860
scanner. The relative amount of footprint signal at each time point with
respect to the 0-h time point was plotted after normalizing the signal in
the Trn1 reaction by the signal in the Trn2 reaction.
FIG. 7. HuF2 releases RNA polymerase I stalled at T<>T.
pHr163-T,.T, radiolabeled at the 13th phosphate 59 to the dimer, was
first transcribed by partially purified human RNA polymerase I and
then incubated with increasing amounts of HuF2 as indicated. The
DNA was then digested with DNase I and analyzed on an 8% sequenc-
ing gel. The sizes of DNA segments protected from DNase I (bracket) are
indicated. Control reaction (Trn2, lane 1) was performed by omitting
CTP from the reaction. M indicates DNA size markers in nucleotides.
FIG. 8. HuF2 does not release E. coli RNA polymerase. Template
1 was transcribed by E. coli RNA polymerase in the presence of ApU, A,
G, and [a-32P]CTP. Stalling at several sites along the template gener-
ated the transcripts indicated as Stalled. HuF2 (to 4 nM) or Mfd (to 10
nM) were added to the reactions as indicated. RNA polymerase was then
chased by adding unlabeled UTP and CTP generating run-off tran-
scripts. RNA polymerase was not chased in the control reaction (lane 1).
Reaction products were extracted, precipitated, and analyzed on a 20%
sequencing gel. Rifampicin was added (to 22 mg/ml) to all of the reac-
tions after formation of stalled ternary complex to avoid transcription
reinitiation during the release and chase reactions. The run-off tran-
scription products are indicated. M indicates DNA size markers in
nucleotides.
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plex (11). Similarly, the addition of CSB, or CSB plus CSA to a
partially purified transcription and repair system did not in-
duce preferential repair of the template strand. Hence, it is
plausible that other factors in addition to CSA and CSB con-
tribute to preferential repair. Thus, it was of interest to test
other factors that are known to have an effect on the elongation
step of transcription on RNA polymerase stalled at a thymine
dimer. Indeed, in a previous study we found that nuclear ex-
tracts contained a “release factor,” which disrupted ternary
complexes formed by RNA polymerase II (11). In this regard,
HuF2 is of special significance because this factor has several
similarities to the prokaryotic transcription-repair coupling
factor TRCF (27, 31); both are DNA stimulated ATPases, and
both release stalled cognate RNA polymerases from transcrip-
tional pause sites. Here we have demonstrated that HuF2
releases RNA polymerase II stalled at a thymine dimer as well.
The present study provides direct evidence of the function of
HuF2 as a RNA polymerase release factor by demonstrating
the displacement of RNA polymerase from the template DNA.
The possible role of HuF2 in transcription machinery is to
retrieve RNA polymerase from template DNA after stalling,
thus making RNA polymerase available for transcription initi-
ation. It is known that human RNA polymerase I and III
transcription termination factors, PTRF (polymerase I and
transcript release factor) and La, respectively, have a stimula-
tory effect on transcription (35, 36).
Unexpectedly, we find that up until now what was thought to
be RNA polymerase II-specific transcription termination factor
works with comparable efficiency on RNA polymerase I. It is
not unprecedented, however, that one transcription elongation
factor has the same effect on two different classes of RNA
polymerase. TFIIS has been shown to have a stimulatory effect
and cause transcript cleavage on both RNA polymerase I and II
transcription at elongation mode (37). These data suggest that
regulatory mechanisms of transcription elongation are shared
among different classes of eukaryotic RNA polymerases. Re-
cently, a factor that induces dissociation of RNA polymerase I
ternary complex paused at terminator sequence, PTRF, was
identified (35). PTRF does not require ATP but requires a
U-run at the 39-end of transcript to exert its function. HuF2, on
the other hand, does not require any specific RNA sequence for
its function based on our results that showed that HuF2 dis-
sociates RNA polymerase stalled at unrelated sequences, the
end of the U-less cassette and the T,.T site. Thus, HuF2
constitutes an additional termination factor for RNA polymer-
ase I transcription.
In the present study, we have found that a thymine cyclobu-
tane dimer in the template strand constitutes an absolute block
for RNA polymerase I and that the stalled polymerase makes a
long lived complex at the site of the lesion. These findings raise
certain questions regarding the stimulation or inhibition of
excision repair by stalled RNA polymerase I.
There is extensive literature on transcription-coupled repair
of genes transcribed by RNA polymerase II (1–5, 30). In con-
trast, there are only a few studies addressing the questions of
the effects of lesions in the rRNA genes on RNA polymerase I
and the effect of RNA polymerase I transcription on repair of
rRNA genes (38–43). This is, in part, due to the fact that rRNA
genes are members of a multigene family, and under physio-
logical conditions only about 30% of the family members are
transcribed (39, 41, 44). This makes the study of the effect of
transcription on repair problematic. Nevertheless, the repair of
thymine dimers and of psoralen monoadducts and cross-links
in rRNA genes has been investigated in vivo by taking special
precautions to separate transcribed from nontranscribed DNA,
and it was found that in rRNA genes transcription was not
coupled to repair (38, 41). Yet, another study that measured the
relative rates of recovery from initial inhibition of rRNA syn-
thesis after UV irradiation found that rRNA synthesis recov-
ered normally in an XP-C cell line but not in other XP cell lines,
suggesting that the transcription-inhibiting photoproducts
were removed from the transcriptionally active rRNA genes
only in XP-C cell (42). Since the same kinetics of RNA synthesis
recovery is observed for genes transcribed by RNA polymerase
II, this finding suggested that transcription-coupled repair ma-
chinery operates on the rRNA gene because XP-C cells are
proficient for transcription-coupled repair but defective in ge-
nome overall repair (45, 46).
Recently, it was observed that in yeast UV photoproducts are
removed from the transcribed strand of rRNA gene in rad7 and
rad16 mutants (43), demonstrating the transcription-coupled
repair of rRNA genes because both rad7 and rad16 mutants are
defective in genome overall repair but proficient in transcrip-
tion-coupled repair, as is the XP-C mammalian mutant (46).
The present study revealed that RNA polymerase I ternary
complex formed at the T,.T has the same biochemical fea-
tures as RNA polymerase II ternary complex, satisfying one of
the potential prerequisites of transcription-coupled repair of
rRNA genes.
Finally, the results presented here show that although CSB
does not release RNA polymerases stalled at a lesion, HuF2
does. Furthermore, HuF2 is a relatively abundant nuclear pro-
tein (15, 16). Hence, any model for transcription-repair cou-
pling that includes the step of targeting of repair proteins by
CSB to a stalled RNA polymerase complex and eventual repair
of the damage without discarding the transcript (47) must take
into account that there is an abundant protein in the nucleus
FIG. 9. Effect of CSB protein on negative transcription elon-
gation activity of HuF2. Stalled RNA polymerase II ternary complex
was formed at the end of the U-less cassette on pMLU112, which
generates transcripts labeled Stalled. After PvuII digestion, CSB pro-
tein was added to the reactions as indicated. Reactions were then
incubated with 4 nM HuF2 and chased by adding unlabeled UTP and
CTP as indicated above the gel. The run-off transcription product is
indicated. DNA markers of the indicated nucleotide length were run in
lane M.
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that rapidly and efficiently dissociates RNA polymerase and
discards the transcript.
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